OBJECTIVE: The objective of this research is to demonstrate the release of SARS-CoV-2 Spike (S) antibodies in human milk samples obtained by patients who have been vaccinated with mRNABNT162b2 vaccine. METHODS: Milk and serum samples were collected in 10 volunteers 20 days after the first dose and 7 seven days after the second dose of the mRNABNT162b2 vaccine. Anti-SARS-CoV-2 S antibodies were measured by the Elecsys® Anti-SARS-CoV-2 S ECLIA assay (Roche Diagnostics AG, Rotkreuz, Switzerland), a quantitative electrochemiluminescence immunometric method. RESULTS: At first sample, anti-SARS-CoV-2 S antibodies were detected in all serum samples (103.9 ± 54.9 U/mL) and only in two (40%) milk samples with a low concentration (1.2 ± 0.3 U/mL). At the second sample, collected 7 days after the second dose, anti-SARS-CoV-2 S antibodies were detected in all serum samples (3875.7 ± 3504.6 UI/mL) and in all milk samples (41.5 ± 47.5 UI/mL). No correlation was found between the level of serum and milk antibodies; the milk antibodies/serum antibodies ratio was on average 2% (range: 0.2-8.4%). CONCLUSION: We demonstrated a release of anti-SARS-CoV-2 S antibodies in the breast milk of women vaccinated with mRNABNT162b2. Vaccinating breastfeeding women could be a strategy to protect their infants from COVID-19 infection.
OBJECTIVE: The objective of this research is to demonstrate the release of SARS-CoV-2Spike (S) antibodies in human milk samples obtained by patients who have been vaccinated with mRNABNT162b2 vaccine. METHODS: Milk and serum samples were collected in 10 volunteers 20 days after the first dose and 7 seven days after the second dose of the mRNABNT162b2 vaccine. Anti-SARS-CoV-2 S antibodies were measured by the Elecsys® Anti-SARS-CoV-2 S ECLIA assay (Roche Diagnostics AG, Rotkreuz, Switzerland), a quantitative electrochemiluminescence immunometric method. RESULTS: At first sample, anti-SARS-CoV-2 S antibodies were detected in all serum samples (103.9 ± 54.9 U/mL) and only in two (40%) milk samples with a low concentration (1.2 ± 0.3 U/mL). At the second sample, collected 7 days after the second dose, anti-SARS-CoV-2 S antibodies were detected in all serum samples (3875.7 ± 3504.6 UI/mL) and in all milk samples (41.5 ± 47.5 UI/mL). No correlation was found between the level of serum and milk antibodies; the milk antibodies/serum antibodies ratio was on average 2% (range: 0.2-8.4%). CONCLUSION: We demonstrated a release of anti-SARS-CoV-2 S antibodies in the breast milk of women vaccinated with mRNABNT162b2. Vaccinating breastfeeding women could be a strategy to protect their infants from COVID-19infection.
Authors: Jiong Wang; Bridget E Young; Dongmei Li; Antti Seppo; Qian Zhou; Alexander Wiltse; Anna Nowak-Wegrzyn; Katherine Murphy; Kaili Widrick; Nicole Diaz; Joseline Cruz-Vasquez; Kirsi M Järvinen; Martin S Zand Journal: Vaccines (Basel) Date: 2022-06-20
Authors: Yarden Golan; Mary Prahl; Arianna G Cassidy; Caryl Gay; Alan H B Wu; Unurzul Jigmeddagva; Christine Y Lin; Veronica J Gonzalez; Emilia Basilio; Megan A Chidboy; Lakshmi Warrier; Sirirak Buarpung; Lin Li; Amy P Murtha; Ifeyinwa V Asiodu; Nadav Ahituv; Valerie J Flaherman; Stephanie L Gaw Journal: Front Immunol Date: 2021-11-03 Impact factor: 7.561
Authors: Hannah G Juncker; Sien J Mulleners; Eliza J M Ruhé; Esmée R M Coenen; Sjors Bakker; Maritt van Doesburg; Jolinda E Harinck; Romee D Rood; Joey H Bouhuijs; Melissa Oomen; Prof Christianne J M de Groot; Prof Dasja Pajkrt; Aniko Korosi; Prof Johannes B van Goudoever; Marit J van Gils; Britt J van Keulen Journal: EClinicalMedicine Date: 2022-04-18
Authors: Joke Muyldermans; Louise De Weerdt; Larissa De Brabandere; Kirsten Maertens; Eline Tommelein Journal: Front Immunol Date: 2022-04-08 Impact factor: 8.786